Results 1 to 10 of about 243,618 (120)

Loss of CASZ1 tumor suppressor linked to oncogenic subversion of neuroblastoma core regulatory circuitry

Cell Death and Disease, 2022
The neural crest lineage regulatory transcription factors (TFs) form a core regulatory circuitry (CRC) in neuroblastoma (NB) to specify a noradrenergic tumor phenotype.
Zhihui Liu, Xiyuan Zhang, Man Xu, Haiyan Lei, Jack F. Shern, Carol J. Thiele   +5 more
doaj   +1 more source

The Needs of Adolescents and Young Adults with Chronic Illness: Results of a Quality Improvement Survey

Children, 2022
Adolescent and young adults (AYAs) with chronic illnesses cope with complex issues that require unique psychological support and healthcare services to reduce psychosocial difficulties, improve disease management, and facilitate positive transitions to ...
Taryn Allen, Stephanie Reda, Staci Martin, Phoebe Long, Alexis Franklin, Sima Zadeh Bedoya, Lori Wiener, Pamela L. Wolters   +7 more
doaj   +1 more source

Characteristics and clinical course of thyroid abnormalities arisen in long term survivors of childhood cancer

BMC Pediatrics, 2023
Background Thyroid abnormality is a common late effect seen in childhood cancer survivors (CCSs). We analyzed the prevalence and risk factors of thyroid abnormalities based on diagnoses and treatment modalities in CCSs. Methods The medical records of 257
Hye Young Jin, Jun Ah. Lee, Meerim Park, Dong-Eun Lee, Hyeon Jin Park   +4 more
doaj   +1 more source

CASZ1 induces skeletal muscle and rhabdomyosarcoma differentiation through a feed-forward loop with MYOD and MYOG

Nature Communications, 2020
Embryonal rhabdomyosarcoma (ERMS) is a childhood cancer with impaired myogenic differentiation despite the presence of myogenic transcription factors. Here, the authors show that CASZ1 directly regulates these myogenic factors and the loss of CASZ1 is ...
Zhihui Liu, Xiyuan Zhang, Haiyan Lei, Norris Lam, Sakereh Carter, Oliver Yockey, Max Xu, Arnulfo Mendoza, Edjay R. Hernandez, Jun S. Wei, Javed Khan, Marielle E. Yohe, Jack F. Shern, Carol J. Thiele   +13 more
doaj   +1 more source

Research on the development of cancer drugs for children [PDF]

E3S Web of Conferences, 2021
The development of pediatric cancer drugs is inefficient and must requires a significant development to improve the current situation. According to the research on the development of pediatric cancer drugs, the market condition is analyzed and compared ...
Wang Yihan
doaj   +1 more source

Structural basis for defective membrane targeting of mutant enzyme in human VLCAD deficiency

Nature Communications, 2022
Prew et al. uncovered a structural basis for human VLCAD deficiency that arises from point mutations within the enzyme’s membrane-binding region, which was shown to fold as a putative α-helical hairpin.
Michelle S. Prew, Christina M. Camara, Thomas Botzanowski, Jamie A. Moroco, Noah B. Bloch, Hannah R. Levy, Hyuk-Soo Seo, Sirano Dhe-Paganon, Gregory H. Bird, Henry D. Herce, Micah A. Gygi, Silvia Escudero, Thomas E. Wales, John R. Engen, Loren D. Walensky   +14 more
doaj   +1 more source

Early post‐induction augmented therapy improves outcome in children and adolescents with T‐cell acute lymphoblastic leukemia

Cancer Reports, 2023
Introduction T‐cell acute lymphoblastic leukemia (T‐ALL) accounts for approximately 15% of all newly diagnosed ALL in children and adolescents and is associated with worse outcomes compared to pre‐B ALL.
Mayada Abu Shanap, Haytham Al Jabour, Rawad Rihani, Hasan Hashem, Amal Abu Ghosh, Abdelghani Tbakhi, Nazmi Kamal, Iyad Sultan, Faris Madanat   +8 more
doaj   +1 more source

Irinotecan Plus Doxorubicin Hydrochloride Liposomes for Relapsed or Refractory Wilms Tumor

Frontiers in Oncology, 2021
PurposeThe prognosis of relapsed or refractory pediatric Wilms tumor (WT) is dismal, and new salvage therapies are needed. This study aimed to evaluate the efficacy of the combination of irinotecan and a doxorubicin hydrochloride liposome regimen for ...
Juan Wang, Lian Zhang, Lanying Guo, Yi Que, Yu Zhang, Feifei Sun, Jia Zhu, Suying Lu, Junting Huang, Liuhong Wu, Ruiqing Cai, Zijun Zhen, Sihui Zeng, Yizhuo Zhang, Xiaofei Sun   +14 more
doaj   +1 more source

Hepatoblastoma: A Need for Cell Lines and Tissue Banks to Develop Targeted Drug Therapies

Frontiers in Pediatrics, 2016
Limited research exists regarding the most aggressive forms of hepatoblastoma. Cell lines of the rare subtypes of hepatoblastoma with poor prognosis are not only difficult to attain, but are challenging to characterize histologically.
Rishi Raj Rikhi, Kimberlee K Spady, Ruth I Hoffman, Michael S Bateman, Max eBateman, Lisa Easom Howard   +5 more
doaj   +1 more source

Novel infusion strategy reduces severe adverse events caused by the anti-GD2 monoclonal antibody naxitamab

Frontiers in Oncology, 2023
IntroductionAnti-disialoganglioside 2 (anti-GD2) monoclonal antibodies (mAbs) are associated with Grade ≥3 (≥G3) adverse events (AEs) such as severe pain, hypotension, and bronchospasm.
Amalia Varo, Alicia Castañeda, Saray Chamorro, Juan Pablo Muñoz, Maite Gorostegui, Mónica S. Celma, Sandra Lopez, Margarida Simao, Sara Perez-Jaume, Jaume Mora   +9 more
doaj   +1 more source